Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

CEA-Leti Announces €1 Million Funding

Published: Thursday, July 04, 2013
Last Updated: Thursday, July 04, 2013
Bookmark and Share
bpifrance (ex OSEO) awarded grant to speed preclinical development of cancer-detecting nanoparticles.

CEA-Leti announced today €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815™.

The grant, awarded through bpifrance ’s Strategic Industrial Innovation (ISI) program, will accelerate the development of LipImage 815™, including production and regulatory toxicity evaluation. It also supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France.

Developed by Leti, LipImage 815™ is a fluorescent imaging agent based on Leti’s Lipidots® platform that uses lipid nanoparticles to carry a fluorescent substance to targeted cells and improve the effectiveness of diagnosis. It will be used to test for early stages of liver cancer.

Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

In addition to Leti, the consortium includes:

•    BioAlliance Pharma, developer of Livatag®, a doxorubicin nanoparticle currently in phase III clinical trial for treatment of primary liver cancer
•    Nanobiotix, developer of NBTXR3, a potentiator of radiation therapy in the local treatment of cancer
•    DBI, a company specialized in the production of nanomedicine pharmaceutical products
•    Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticles research

“By bringing together a highly experienced team of specialists in various fields of nanomedicine, this program can significantly accelerate the development of an effective new tool for diagnosing liver cancer,” said Laurent Malier, Leti CEO. “It also leverages Leti’s achievements in the Lipidots® platform, and provides another avenue for us to bring our innovations to market.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leti and Diabeloop Project Aims at Developing Artificial Pancreas
Artificial pancreas will automatically deliver the appropriate dose of insulin to patients.
Saturday, July 25, 2015
Leti Announces Launch of First European Nanomedicine Characterization Laboratory
Project combines expertise of 9 partners in 8 countries to foster nanomedicine innovation and facilitate regulatory approval.
Tuesday, July 07, 2015
Eveon, Leti Mark Milestone in Fabrication of Smart Bolus-type Micro-pump
Both Companies announces the demonstration of liquid-pumping for smart drug delivery.
Friday, March 14, 2014
Leti Announces Project to Develop New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Tuesday, February 18, 2014
PIEZOMAT Project Targets New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Thursday, February 13, 2014
Leti Announces MEMS Research Collaboration with OMRON
Leti’s first collaboration with a Japanese MEMS producer.
Monday, December 09, 2013
CEA-Leti Signs Agreement with Qualcomm
Agreement to assess Leti’s sequential 3D technology.
Monday, December 09, 2013
Alim-Louis Benabid Honored by U.S. Research Institute
Benabid has received the Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.
Friday, October 11, 2013
Patrick Boisseau Elected Chairman of the ETPN
Program will focus on building a structure that speeds innovations’ time to market and patients, while keeping Europe’s nanomed IP at home.
Monday, March 25, 2013
Attolight and Leti Launch Joint-Development Program
Program to extend applications for Company’s cathodoluminescence technology.
Monday, October 29, 2012
CEA-Leti and 7 Partners to Study Ways to Improve Treatment of Inflammatory Bowel Disease
Goal is to develop nanocarrier for targeted delivery of corticosteroids and immunosuppressants.
Thursday, April 14, 2011
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos